Figure 4.
Figure 4. The association of miR-150 expression with biological characteristics of FL and survival of patients. (A) miR-150 expression in FL patients divided according to terciles of Ki67 proliferation index (the differences were tested by Mann-Whitney test). All samples with available data on Ki67 were used in the analysis. (B) miR-150 expression in FL patients divided according to Follicular Lymphoma International Prognostic Index (FLIPI) score (the differences were tested by Mann-Whitney test). All samples with available data on FLIPI were used in the analysis. (C-E) Association of miR-150 expression with OS in FL. The OS is depicted using the Kaplan-Meier curves (with log-rank test) in the FL cohort divided by median miR-150 expression (C) or by dividing the cohort into 3 (D) or 4 (E) groups based on terciles or quartiles of miR-150 expression, respectively. For all analyses, only patients with histologically verified FL at the time of sampling (with no histopathological signs of transformation to DLBCL) were included. Patient characteristics are listed in supplemental Table 2. (F) Differences in miR-150 levels between FL patients who experienced early death within 3 years from biopsy (death <3 years) or who died later (death >3 years) or are still alive for longer than 3 years (alive >3 years) from biopsy. One patient with a follow-up time <3 years was excluded from the analysis. Similar data were obtained when only samples obtained at diagnosis were included in the analysis (54 of 84 samples; supplemental Figure 17A) or in patients experiencing early relapse (<24 months; supplemental Figure 17B). For all analyses, only patients with histologically verified FL at the time of sampling (with no histopathological signs of transformation to DLBCL) were included. The differences in miR-150 levels between individual groups were tested by Mann-Whitney test. (G) The OS in FL patients divided according to immunostaining for FOXP1 (30 FL patients with material available as tissue microarray blocks; supplemental Methods). The patients were divided into 3 groups of samples with low (≤30%), intermediate (inter; 30%-70%), or high (≥70%) percentage of FOXP1+ cells. For all analyses, only patients with histologically verified FL at the time of sampling (with no histopathological signs of transformation to DLBCL) were included. Representative images of the scoring of FOXP1 staining in FL are shown in supplemental Figure 14. NS, not significant.

The association of miR-150 expression with biological characteristics of FL and survival of patients. (A) miR-150 expression in FL patients divided according to terciles of Ki67 proliferation index (the differences were tested by Mann-Whitney test). All samples with available data on Ki67 were used in the analysis. (B) miR-150 expression in FL patients divided according to Follicular Lymphoma International Prognostic Index (FLIPI) score (the differences were tested by Mann-Whitney test). All samples with available data on FLIPI were used in the analysis. (C-E) Association of miR-150 expression with OS in FL. The OS is depicted using the Kaplan-Meier curves (with log-rank test) in the FL cohort divided by median miR-150 expression (C) or by dividing the cohort into 3 (D) or 4 (E) groups based on terciles or quartiles of miR-150 expression, respectively. For all analyses, only patients with histologically verified FL at the time of sampling (with no histopathological signs of transformation to DLBCL) were included. Patient characteristics are listed in supplemental Table 2. (F) Differences in miR-150 levels between FL patients who experienced early death within 3 years from biopsy (death <3 years) or who died later (death >3 years) or are still alive for longer than 3 years (alive >3 years) from biopsy. One patient with a follow-up time <3 years was excluded from the analysis. Similar data were obtained when only samples obtained at diagnosis were included in the analysis (54 of 84 samples; supplemental Figure 17A) or in patients experiencing early relapse (<24 months; supplemental Figure 17B). For all analyses, only patients with histologically verified FL at the time of sampling (with no histopathological signs of transformation to DLBCL) were included. The differences in miR-150 levels between individual groups were tested by Mann-Whitney test. (G) The OS in FL patients divided according to immunostaining for FOXP1 (30 FL patients with material available as tissue microarray blocks; supplemental Methods). The patients were divided into 3 groups of samples with low (≤30%), intermediate (inter; 30%-70%), or high (≥70%) percentage of FOXP1+ cells. For all analyses, only patients with histologically verified FL at the time of sampling (with no histopathological signs of transformation to DLBCL) were included. Representative images of the scoring of FOXP1 staining in FL are shown in supplemental Figure 14. NS, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal